Loading organizations...
§ Venture Capital · MA, USA
Life sciences venture capital firm creating & investing in biotech, healthcare, therapeutics, medical devices, diagnostics.
Founded in 1999 by managing partner Seth Harrison, ATP (Apple Tree Partners) is a life sciences venture capital firm based in New York that creates and invests in early-stage biotechnology, therapeutics, diagnostics, and medical device companies. The firm manages over $2.65 billion in committed capital across its funds and operates with an estimated team of 21 to 50 employees, incubating startups from the pre-IPO stage through successful exits. Its investment portfolio features notable healthcare and biotech startups, including Akero Therapeutics, Ascidian Therapeutics, Replicate Bioscience, and Aulos Bioscience. ATP recently facilitated a major milestone as portfolio company Ascidian Therapeutics announced a research collaboration and licensing agreement with Roche potentially worth up to $1.8 billion. In December 2025, the firm filed for voluntary Chapter 11 bankruptcy to restructure its operations while ensuring its active portfolio companies maintain funding resources.
Key people at ATP (Apple Tree Partners).
Key people at ATP (Apple Tree Partners).
ATP (Apple Tree Partners) has more than 26 tracked investments across 17 companies. The latest tracked deal is $100.0M Series C in Galvanize Therapeutics in September 2025.
Apple Tree Partners (ATP) is a leading venture capital firm specializing in life sciences, particularly in creating and investing in transformative biotechnology companies. Founded in 1999, ATP manages $2.9 billion in committed capital and operates from offices in New York, South San Francisco, and Cambridge, MA. The firm invests across all stages, from pre-IP scientific ideas to asset spinouts, supporting companies from seed stage through IPO and beyond. ATP’s mission centers on providing flexible capital and strategic, operational resources to build sustainable, research-driven enterprises that improve human health. Their portfolio includes companies developing novel therapeutics and medical devices targeting oncology, metabolic, inflammatory, and pulmonary diseases, reflecting a strong impact on the biotech startup ecosystem by fostering innovation and commercialization of cutting-edge life sciences technologies[1][2][5].
Apple Tree Partners was founded in 1999 by Dr. Seth Harrison and other key partners, evolving into a prominent life sciences venture capital firm with a unique model that combines capital provision with hands-on operational support. Over time, ATP has expanded its focus to include AI and machine learning applications in drug discovery, exemplified by initiatives like Deep Apple Therapeutics. The firm has been instrumental in launching over 30 life sciences companies, with 19 having gone public or been acquired, demonstrating a track record of successful exits and value creation. ATP’s evolution reflects a deepening integration of scientific expertise and entrepreneurial rigor to accelerate the development of transformative biotech enterprises[2][5][7].
ATP rides the wave of increasing convergence between biotechnology and advanced computational technologies like AI and machine learning, which are transforming drug discovery and development. The timing is critical as the biotech sector experiences rapid innovation cycles and growing demand for novel therapies addressing unmet medical needs. Market forces such as rising healthcare challenges, regulatory support for innovation, and expanding global biotech ecosystems favor ATP’s model. By creating and scaling research-driven companies, ATP influences the broader life sciences ecosystem, accelerating the translation of scientific breakthroughs into impactful therapies and medical technologies[5][6].
Looking ahead, Apple Tree Partners is poised to deepen its integration of AI and computational methods in biotech, expanding its portfolio in precision medicine and novel therapeutic areas. Trends such as personalized medicine, digital health convergence, and advanced biologics will likely shape their investment focus. ATP’s influence is expected to grow as it continues to pioneer flexible capital deployment combined with operational expertise, helping startups overcome traditional biotech development hurdles. This positions ATP as a critical enabler of next-generation life sciences innovation, sustaining its leadership role in the venture capital landscape[5].
In summary, Apple Tree Partners stands out as a venture capital firm that not only funds but actively builds transformative biotech companies, leveraging deep scientific expertise and operational support to improve human health outcomes.